Angela Shen, MD, provides expertise in translational medicine and clinical development for novel therapies being developed at Mass General Brigham, with a focus on the gene & cell therapy portfolio. Prior to joining Mass General Brigham, Angela has served as chief medical officer (CMO) of multiple biotech startups, including Arcellx, Nkarta, Arvinas, and acting CMO of Tizona. Angela has led oncology programs in a variety of pharmaceutical settings for over 15 years through all stages of drug development, including IND filings, first-in-human trials, registrational trials, and NDA/BLA filings. While working in oncology clinical development at Novartis, Angela was extensively involved with in-licensing the University of Pennsylvania’s CAR-T technology. She assembled and led the clinical team responsible for designing and launching the industry’s first multi-site, registration CAR-T trial, which resulted in the approval of Kymriah® (CTL019, CART-19). Prior to that, Angela made key contributions to the development of several oncology drugs within Novartis, Exelixis, and Johnson & Johnson that were subsequently approved.
Angela has unique, deep knowledge of the cell and gene therapy landscape, having provided clinical, regulatory, and strategic leadership for autologous and allogeneic CAR-T therapies, NK cell therapies, and other novel cell therapy programs across the industry. She received a BS through Rensselaer’s accelerated biomedical program and holds an MD from Albany Medical College in New York and an MBA from New York University Stern School of Business.